AU2019214048B2 - Nitrogenated heterocyclic amide compound, and use thereof for medical purposes - Google Patents

Nitrogenated heterocyclic amide compound, and use thereof for medical purposes Download PDF

Info

Publication number
AU2019214048B2
AU2019214048B2 AU2019214048A AU2019214048A AU2019214048B2 AU 2019214048 B2 AU2019214048 B2 AU 2019214048B2 AU 2019214048 A AU2019214048 A AU 2019214048A AU 2019214048 A AU2019214048 A AU 2019214048A AU 2019214048 B2 AU2019214048 B2 AU 2019214048B2
Authority
AU
Australia
Prior art keywords
compound
formula
pharmaceutically acceptable
acceptable salt
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2019214048A
Other languages
English (en)
Other versions
AU2019214048A1 (en
Inventor
Masayuki KOTOKU
Takaki MAEBA
Ritsuki Masuo
Dai Motoda
Koichi Suzawa
Nobutaka YAMAOKA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shionogi and Co Ltd
Original Assignee
Shionogi and Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shionogi and Co Ltd filed Critical Shionogi and Co Ltd
Publication of AU2019214048A1 publication Critical patent/AU2019214048A1/en
Application granted granted Critical
Publication of AU2019214048B2 publication Critical patent/AU2019214048B2/en
Assigned to SHIONOGI & CO., LTD. reassignment SHIONOGI & CO., LTD. Request to Amend Deed and Register Assignors: JAPAN TOBACCO INC.
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/99—Enzyme inactivation by chemical treatment

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Hospice & Palliative Care (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Microbiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biotechnology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
AU2019214048A 2018-02-01 2019-01-30 Nitrogenated heterocyclic amide compound, and use thereof for medical purposes Active AU2019214048B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2018016328 2018-02-01
JP2018-016328 2018-02-01
PCT/JP2019/003052 WO2019151274A1 (ja) 2018-02-01 2019-01-30 含窒素複素環アミド化合物及びその医薬用途

Publications (2)

Publication Number Publication Date
AU2019214048A1 AU2019214048A1 (en) 2020-06-25
AU2019214048B2 true AU2019214048B2 (en) 2023-03-16

Family

ID=67479787

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2019214048A Active AU2019214048B2 (en) 2018-02-01 2019-01-30 Nitrogenated heterocyclic amide compound, and use thereof for medical purposes

Country Status (21)

Country Link
US (4) US10800784B2 (https=)
EP (1) EP3747888A4 (https=)
JP (3) JP7241556B2 (https=)
KR (1) KR102725118B1 (https=)
CN (1) CN111655692B (https=)
AR (1) AR114237A1 (https=)
AU (1) AU2019214048B2 (https=)
BR (1) BR112020014177A2 (https=)
CA (1) CA3090219A1 (https=)
CL (1) CL2020002003A1 (https=)
CO (1) CO2020009420A2 (https=)
IL (1) IL276386B2 (https=)
MX (1) MX2020008126A (https=)
MY (1) MY205011A (https=)
PE (1) PE20211273A1 (https=)
PH (1) PH12020500613A1 (https=)
SA (1) SA520412473B1 (https=)
SG (1) SG11202006916SA (https=)
TW (1) TWI803570B (https=)
WO (1) WO2019151274A1 (https=)
ZA (1) ZA202004548B (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112638377A (zh) 2018-09-11 2021-04-09 日本烟草产业株式会社 含有吡唑酰胺化合物的慢性肾脏病的治疗或预防剂
CN110407744A (zh) * 2019-08-13 2019-11-05 上海毕得医药科技有限公司 一种1-(4-氨基吡啶-2-基)乙酮的合成方法
HRP20241159T1 (hr) 2020-02-07 2024-12-06 Gasherbrum Bio, Inc. Heterociklički agonisti za glp-1
PL4116301T3 (pl) * 2020-03-04 2026-02-16 Japan Tobacco Inc. Skondensowany związek tricykliczny i jego zastosowanie medyczne
CN116368140A (zh) * 2020-09-10 2023-06-30 加舒布鲁姆生物公司 杂环glp-1激动剂
US20240025924A1 (en) * 2021-03-23 2024-01-25 Shanghai Haiyan Pharmaceutical Technology Co., Ltd. Heterocycle substituted ketone derivative, and composition and medicinal use thereof
AU2022337617A1 (en) 2021-09-01 2024-04-18 Japan Tobacco Inc. Nitrogen-containing tricyclic compound and pharmaceutical use thereof
CN120957993A (zh) 2023-02-16 2025-11-14 加舒布鲁姆生物公司 杂环glp-1激动剂

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015002119A1 (ja) * 2013-07-01 2015-01-08 日本たばこ産業株式会社 ピラゾール－アルコール化合物およびその医薬用途
WO2017020981A1 (en) * 2015-07-31 2017-02-09 Merck Patent Gmbh Bicyclic heterocyclic derivatives

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7943617B2 (en) * 2006-11-27 2011-05-17 Bristol-Myers Squibb Company Heterobicyclic compounds useful as kinase inhibitors
WO2008132162A1 (en) * 2007-04-26 2008-11-06 Boehringer Ingelheim International Gmbh 3- (sulphonylamino) -phenyl-2 -hydroxy-ethylamino derivatives useful as beta-agonists, processes for preparing them and their use as medicaments
CA2689930A1 (en) 2007-06-01 2008-12-18 Schering Corporation Gamma secretase modulators
EP2090576A1 (en) * 2008-02-01 2009-08-19 Merz Pharma GmbH & Co.KGaA 6-halo-pyrazolo[1,5-a]pyridines, a process for their preparation and their use as metabotropic glutamate receptor (mGluR) modulators
AR074797A1 (es) * 2008-10-10 2011-02-16 Japan Tobacco Inc Compuesto de fluoreno , composiciones farmaceuticas , inhibidores de pdhk y pdhk2 , metodos de tratamiento , usos de los mismos y kit comercial
CN103889996B (zh) * 2011-06-27 2016-02-03 阿列科托斯治疗有限公司 选择性糖苷酶抑制剂及其用途
WO2013074388A1 (en) 2011-11-15 2013-05-23 Merck Sharp & Dohme Corp. Substituted cyclopropyl compounds useful as gpr119 agonists
DK2858986T3 (da) 2012-06-12 2019-11-25 Chong Kun Dang Pharmaceutical Corp Piperidinderivater som gpr119-agonister
CN103570725B (zh) 2012-08-01 2017-03-22 中国科学院上海药物研究所 哌嗪并三唑类化合物及其制备方法和用途
BR112015022077A2 (pt) * 2013-03-15 2017-07-18 Japan Tobacco Inc composto de pirazol-amida e usos medicinais do mesmo
US20150018403A1 (en) * 2013-07-01 2015-01-15 Japan Tobacco Inc. Fluorene-amide compounds and pharmaceutical use thereof
GB201316823D0 (en) 2013-09-23 2013-11-06 R & D Vernalis Ltd New Chemical Entities
ES2665148T3 (es) 2013-12-17 2018-04-24 Merck Patent Gmbh Derivados de N1-(3,3,3-trifluoro-2-hidroxo-2-metilpropionil)-piperidina como inhibidores de la piruvato deshidrogenasa quinasa
US11026936B2 (en) 2016-03-29 2021-06-08 Merck Patent Gmbh Piperidinyl-propanone derivatives
CN109071490B (zh) * 2016-04-28 2021-04-06 默克专利股份公司 哌啶基衍生物
KR20190036549A (ko) * 2016-07-29 2019-04-04 니뽄 다바코 산교 가부시키가이샤 피라졸-아미드 화합물의 제조 방법
WO2018034918A1 (en) * 2016-08-15 2018-02-22 Merck Sharp & Dohme Corp. Compounds useful for altering the levels of bile acids for the treatment of diabetes and cardiometabolic disease
AU2017350473A1 (en) 2016-10-28 2019-04-18 H. Lundbeck A/S Combination treatments comprising imidazopyrazinones for the treatment of psychiatric and/or cognitive disorders
WO2018078042A1 (en) 2016-10-28 2018-05-03 H. Lundbeck A/S Combination treatments comprising administration of imidazopyrazinones
PL4116301T3 (pl) * 2020-03-04 2026-02-16 Japan Tobacco Inc. Skondensowany związek tricykliczny i jego zastosowanie medyczne
AU2022337617A1 (en) * 2021-09-01 2024-04-18 Japan Tobacco Inc. Nitrogen-containing tricyclic compound and pharmaceutical use thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015002119A1 (ja) * 2013-07-01 2015-01-08 日本たばこ産業株式会社 ピラゾール－アルコール化合物およびその医薬用途
WO2017020981A1 (en) * 2015-07-31 2017-02-09 Merck Patent Gmbh Bicyclic heterocyclic derivatives

Also Published As

Publication number Publication date
WO2019151274A1 (ja) 2019-08-08
CN111655692B (zh) 2023-10-10
PH12020500613A1 (en) 2021-05-31
JP7241556B2 (ja) 2023-03-17
KR102725118B1 (ko) 2024-11-04
BR112020014177A2 (pt) 2020-12-08
US20240300952A1 (en) 2024-09-12
US20210284644A1 (en) 2021-09-16
SG11202006916SA (en) 2020-08-28
JP2023071925A (ja) 2023-05-23
TWI803570B (zh) 2023-06-01
CL2020002003A1 (es) 2020-10-23
KR20200115566A (ko) 2020-10-07
CO2020009420A2 (es) 2020-08-10
MX2020008126A (es) 2020-09-18
US20260070910A1 (en) 2026-03-12
EP3747888A4 (en) 2021-12-15
RU2020128593A (ru) 2022-03-03
JP2024116307A (ja) 2024-08-27
EP3747888A1 (en) 2020-12-09
JP2019131544A (ja) 2019-08-08
CA3090219A1 (en) 2019-08-08
US20200017505A1 (en) 2020-01-16
SA520412473B1 (ar) 2023-02-12
TW201934553A (zh) 2019-09-01
MY205011A (en) 2024-09-27
IL276386A (en) 2020-09-30
ZA202004548B (en) 2021-10-27
PE20211273A1 (es) 2021-07-19
US10800784B2 (en) 2020-10-13
AR114237A1 (es) 2020-08-05
AU2019214048A1 (en) 2020-06-25
IL276386B2 (en) 2023-06-01
CN111655692A (zh) 2020-09-11

Similar Documents

Publication Publication Date Title
AU2019214048B2 (en) Nitrogenated heterocyclic amide compound, and use thereof for medical purposes
JP2022071046A (ja) Ｗｄｒ５タンパク質－タンパク質結合の阻害剤
EP2691399B1 (en) Thiazolopyrimidine compounds
JP5520377B2 (ja) Ｊａｋの三環系阻害剤
EP2742049A1 (en) Tricyclic heterocyclic compounds and jak inhibitors
JP2010132689A (ja) ジヒドロピラゾロピリミジノン誘導体
EP2475667A1 (en) Inhibitors of jak
JP2013533868A (ja) タンパク質チロシンキナーゼ阻害剤としての新規ホモピペラジン誘導体およびそれらの医薬使用
JP2023519666A (ja) Ｇｐｒ５２モジュレーター化合物
CA3166747A1 (en) Fused tricyclic compound and medicinal use thereof
AU2022337617A1 (en) Nitrogen-containing tricyclic compound and pharmaceutical use thereof
RU2789670C2 (ru) Азотсодержащий гетероциклический амид и его применение для медицинских целей
HK40041663A (en) Nitrogenated heterocyclic amide compound, and use thereof for medical purposes
JP7618898B1 (ja) ヒト呼吸器合胞体ウイルス及びメタニューモウイルスの阻害薬
TW202122386A (zh) 經取代的1,3-苯基雜芳基衍生物及其在治療疾病中之用途

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
HB Alteration of name in register

Owner name: SHIONOGI & CO., LTD.

Free format text: FORMER NAME(S): JAPAN TOBACCO INC.